MacroGenics. has filed a patent for a dosing regimen involving a PD-1×CTLA-4 bispecific molecule for the treatment of cancer. The patent also covers the use of pharmaceutical compositions and kits containing the molecule. The method involves administering the molecule at a dose of 3 mg/kg to 10 mg/kg once every 3 weeks. GlobalData’s report on MacroGenics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights MacroGenics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on MacroGenics, Personalized cancer vaccines was a key innovation area identified from patents. MacroGenics's grant share as of September 2023 was 40%. Grant share is based on the ratio of number of grants to total number of patents.

The patent is filed for a dosing regimen for administering a pd-1×ctla-4 bispecific molecule for cancer treatment

Source: United States Patent and Trademark Office (USPTO). Credit: MacroGenics Inc

A recently filed patent (Publication Number: US20230312756A1) describes a method for treating cancer and stimulating immune cells using a PD-1×CTLA-4 bispecific molecule. The method involves administering the bispecific molecule to a subject in need at a dose of about 3 mg/kg to about 10 mg/kg once every 3 weeks. The bispecific molecule consists of a PD-1 Binding Domain and a CTLA-4 Binding Domain.

The patent claims also specify that the PD-1×CTLA-4 bispecific molecule can be administered during an induction period, which lasts up to 24 weeks, and a maintenance period, which lasts up to 84 weeks. The bispecific molecule can be administered by intravenous infusion.

The PD-1×CTLA-4 bispecific molecule described in the patent has specific amino acid sequences for the PD-1 Binding Domain and the CTLA-4 Binding Domain. It can also include a Hinge Domain and an Fc Region of an IgG1, IgG2, IgG3, or IgG4 isotype. The Fc Region can be a variant Fc Region with amino acid modifications that reduce the affinity for an Fc?R or enhance the serum half-life.

The patent also covers the use of a diabody form of the PD-1×CTLA-4 bispecific molecule, which consists of one or two polypeptide chains with specific amino acid sequences.

The method described in the patent can be used for the treatment of various types of cancer, including but not limited to cervical cancer, head and neck cancer, lung cancer, melanoma, prostate cancer, renal cancer, and soft-tissue sarcoma.

The patent also includes a pharmaceutical kit comprising the PD-1×CTLA-4 bispecific molecule and instructional material for its use in accordance with the described method. The kit can be used for the treatment of cancer or for stimulating immune cells.

It is important to note that the information provided is based solely on the claims made in the filed patent and does not include any additional data or research findings.

To know more about GlobalData’s detailed insights on MacroGenics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies